Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS – Q1 2019 REVENUES REACH A RECORD HIGH OF $9.1 M, A 43% INCREASE

14 January 2019

Quebec City, Quebec, January 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues totaled $9.1 M in the first quarter of 2019 compared with $6.4 M in the corresponding period in 2018, an increase of $2.7 M or 43% and…

Read more

OPSENS’ dPR OBTAINS CE MARKING TO SELL IN EUROPE

9 January 2019

Quebec City, Quebec, January 9, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has been granted CE marking for its diastolic pressure algorithm (“dPR”). Opsens’ dPR algorithm has been designed to assess intracoronary pressure with the heart at rest to diagnose coronary disease without the injection of heart-stimulating medication. Opsens’ diastolic pressure ratio…

Read more